Potential of Mirabegron and its Extended-Release Formulations for the Treatment of Overactive Bladder Syndrome

Author(s): Pankaj Mandpe, Bala Prabhakar, Pravin Shende*.

Journal Name: Current Drug Metabolism

Volume 21 , Issue 2 , 2020

Become EABM
Become Reviewer


Background: Overactive bladder syndrome is a broadly occurring urological disorder with a distressing impact on the quality of life. The commonly used antimuscarinic drugs show poor patient compliance because of unsatisfactory potency, tolerability and high occurrence of adverse effects such as dry mouth, blurred vision, constipation, dizziness etc. Mirabegron is the first approved β3-adrenoreceptor agonist, used as mono or in combination therapies for overactive bladder syndrome.

Objective: The present review provides an insight into the mechanism, pharmacokinetics, toxicokinetics, clinical trials and the development of various conventional and modified-release dosage forms of mirabegron for the treatment of overactive bladder syndrome.

Results: The clinical trials of phase II and phase III of mirabegron demonstrated symptomatic relief from the overactive bladder without disturbing the micturition cycle. To date, mirabegron showed promising results for safety, tolerability and efficacy in patients with overactive bladder syndrome. The modified-release tablet dosage form of mirabegron appear to be a proficient and suitable replacement for antimuscarinics and revealed the tremendous potential to overcome the adverse effects of conventional antimuscarinic drugs like Oxybutyline chloride ER, Detrol LA, VESIcare, etc.

Conclusion: Mirabegron shows a distinct mode of action, i.e., targeting β3-adrenoreceptors and improving bladder storage without altering void contractions. The limited side effects, high safety, efficacy and tolerability of mirabegron present an adequate substitute to antimuscarinics. However, long-term analysis and clinical studies are prerequisites for assessing the safety, tolerability and efficacy profile of mirabegron.

Keywords: Mirabegron, antimuscarinics, overactive bladder, modified-release, mechanism, pharmacokinetic.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Page: [79 - 88]
Pages: 10
DOI: 10.2174/1389200221666200425211139
Price: $95

Article Metrics

PDF: 9